Central nervous system (CNS) progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.
Darlene Dobkowski, MA
Advertisement
Articles by Darlene Dobkowski, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD
5